Lorlatinib as a treatment for ALK-positive lung cancer.

Aminopyridines / therapeutic use Anaplastic Lymphoma Kinase / genetics Carcinoma, Non-Small-Cell Lung / drug therapy Humans Lactams Lactams, Macrocyclic / pharmacology Lung Neoplasms / chemically induced Protein Kinase Inhibitors / adverse effects Pyrazoles
brain metastasis pharmacodynamics pharmacokinetics real-world data resistance treatment sequence

Journal

Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629

Informations de publication

Date de publication:
Aug 2022
Historique:
pubmed: 6 7 2022
medline: 16 7 2022
entrez: 5 7 2022
Statut: ppublish

Résumé

Lorlatinib, a third-generation ALK tyrosine kinase inhibitor, has been approved as a treatment for ALK-positive lung cancer. This review provides information regarding the pharmacology and clinical features of lorlatinib, including its efficacy and associated adverse events. Pivotal clinical trials are discussed along with the current status of lorlatinib as a treatment for ALK-positive lung cancer and future therapeutic challenges. Lorlatinib has been approved as a new standard treatment for lung cancer with gene alteration known as ALK fusion. This review provides information regarding the characteristics of lorlatinib, including its efficacy and the unexpected medical problems that occur during treatment. Today, treatment of ALK-positive lung cancer is more complicated because of the active development of drugs like lorlatinib. This review demonstrates the logic of including lorlatinib as part of the treatment plan and sheds light on the future of treatment for ALK-positive lung cancer.

Autres résumés

Type: plain-language-summary (eng)
Lorlatinib has been approved as a new standard treatment for lung cancer with gene alteration known as ALK fusion. This review provides information regarding the characteristics of lorlatinib, including its efficacy and the unexpected medical problems that occur during treatment. Today, treatment of ALK-positive lung cancer is more complicated because of the active development of drugs like lorlatinib. This review demonstrates the logic of including lorlatinib as part of the treatment plan and sheds light on the future of treatment for ALK-positive lung cancer.

Identifiants

DOI: 10.2217/fon-2022-0184 PMID: 35787143
pubmed: 35787143
doi: 10.2217/fon-2022-0184
doi:

Substances chimiques

Aminopyridines 0
Lactams 0
Lactams, Macrocyclic 0
Protein Kinase Inhibitors 0
Pyrazoles 0
Anaplastic Lymphoma Kinase EC 2.7.10.1
lorlatinib OSP71S83EU

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

2745-2766

Auteurs

Keisuke Baba (K)

Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
ORCID: 0000-0001-9215-7539

Yasushi Goto (Y)

Department of Thoracic Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan.
ORCID: 0000-0002-7437-5054

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridines › Aminopyridines › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs à activité tyrosine kinase › Kinase du lymphome anaplasique › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Tumeurs des bronches › Carcinome bronchogénique › Carcinome pulmonaire non à petites cellules › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Lactames › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Composés polycycliques › Composés macrocycliques › Lactames macrocycliques › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Lorlatinib as a treatment for ALK-positive lung cancer.
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Azoles › Pyrazoles › Lorlatinib as a treatment for ALK-positive lung cancer.